# NIH grant: A novel bioactive bone graft to promote accelerated bone regeneration (1R44AR086679-01A1) — retained record

> Retained us-gov-api record from us-gov-api:nih-reporter.

Canonical: https://highsignal.app/data/records/9e452c88c2eb6e30

[← sources](https://highsignal.app/data)


source: [us-gov-api](https://highsignal.app/data/us-gov-api) (us-gov-api:nih-reporter)  published 2026-09-05 00:00 ingested 2026-09-07 07:26

[original source ↗](https://reporter.nih.gov/project-details/1R44AR086679-01A1)

## retained text



```
NIH grant 1R44AR086679-01A1: A novel bioactive bone graft to promote accelerated bone regeneration
Institute: {'code': 'AR', 'abbreviation': 'NIAMS', 'name': 'National Institute of Arthritis and Musculoskeletal and Skin Diseases', 'admin_org_id': '12500006', 'admin_funding_url': ''}. PI: Sungwoo  Kim. Award: $1262374.
Start: 2026-09-05T00:00:00.
Abstract
There is a critical need to address the significant challenges of repairing large bone defects and nonunion.
These major bone injuries exceed 4-5 cm in length and may be caused by trauma, disease or tumor resection.
They affect nearly half a million out of the 7 million patients who suffer from orthopedic trauma in the US each
year. In contrast to simpler fractures (~2cm) which retain self-regeneration capacity, these large defects
require complex reconstructive procedures associated with high procedural risk, high costs, substantial long-
term discomfort and disability for patients and persistent rates of failure. Current treatments, including the
Ilizarov technique (prolonged consolidation period), the Masquelet technique (multiple surgeries), and free
vascularized fibular bone grafts (refracture rates of 15–40%), rely heavily on bone grafting, which is limited by
donor supply. While BMP2- based therapies show promise, existing delivery methods using absorbable
collagen sponges result in rapid, uncontrolled release, necessitating high doses and causing complications. To
address this, we developed osteoinductive HyTEC technology, which enables sustained BMP2 release and
demonstrated superior bone regeneration and healing in preclinical rat and ovine models compared to
autografts and rapid-release BMP2. Building on these advancements, Tissuerate is developing a clinically
applicable 3D-printed Modular Bioactive Synthetic Bone Graft Technology (MST) based on HyTEC. This
project will develop MST for a sheep critical-sized defect model, ensure GLP-compliant device manufacturing,
and demonstrate MST’s efficacy in promoting accelerated healing compared to autografts. Successful
outcomes will enable commercialization of this bioactive graft, offering a transformative solution for orthopedic
trauma and disorders.
```



document fetched 2026-09-10 22:51